Patent 7928205 was granted and assigned to Amgen on April, 2011 by the United States Patent and Trademark Office.
The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.